Atyr Pharma plans to launch a new global clinical trial to test its investigational therapy, efzofitimod, in people with pulmonary sarcoidosis and a restrictive profile, in which the lungs cannot fully expand. The decision follows a type C meeting with the U.S. Food and Drug Administration (FDA) to discuss…